Back to results
US 2026/0308256 A1Published application
Combinations of anti-ctla-4 antibodies and anti-pd-1 antibodies and therapeutic uses thereof
AssigneesOncoc4, Inc., AcroImmune Biopharma Co., Ltd.
InventorsYang Liu, Pan Zheng, Martin Devenport, Vadim Tsvetnitsky, Xianfeng Fang, Qunmin Zhou, Libing Mu
Life of this patent
Estimating the term…
Abstract
Provided herein are combinations of anti-CTLA-4 antibodies and anti-PD-1 antibodies and uses thereof for treating cancer.
Claims31
A composition comprising an anti-CTLA-4 antibody and an anti-PD-1 antibody, wherein:
- (a) the anti-CTLA-4 antibody comprises (i) a light chain variable region comprising a complementarity determining region (CDR) 1 comprising the sequence set forth in SEQ ID NO:
- 1, a CDR2 comprising the sequence set forth in SEQ ID NO:
- 3, and a CDR3 comprising the sequence set forth in SEQ ID NO:
- 5;
- and (ii) a heavy chain variable region comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
- 6, a CDR2 comprising the sequence set forth in SEQ ID NO:
- 9, and a CDR3 comprising the sequence set forth in SEQ ID NO:
- 10;
- and
- (b) the anti-PD-1 antibody comprises (i) a light chain variable region comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
- 25, a CDR2 comprising the sequence set forth in SEQ ID NO:
- 26, and a CDR3 comprising the sequence set forth in SEQ ID NO:
- 27;
- and (ii) a heavy chain variable region comprising a CDR1 comprising the sequence set forth in SEQ ID NO:
- 31, a CDR2 comprising the sequence set forth in SEQ ID NO:
- 32, and a CDR3 comprising the sequence set forth in SEQ ID NO:
- 33.
14 more elements
A composition comprising an anti-CTLA-4 antibody and an anti-PD-1 antibody, wherein:
- (a) the anti-CTLA-4 antibody comprises a light chain comprising the sequence set forth in SEQ ID NO:
- 23 and a heavy chain comprising the sequence set forth in SEQ ID NO:
- 21;
- (b) the anti-PD-1 antibody comprises a light chain comprising the sequence set forth in SEQ ID NO:
- 30 and a heavy chain comprising the sequence set forth in SEQ ID NO:
- 37;
- (c) the composition comprises 20 mM histidine buffer, 8.8% (w/v) α, α-trehalose dihydrate, 0.06% (w/v) PS80, and 0.2 mM EDTA·2Na·2H2O;
- and
- (d) the pH of the composition is 6.0.
6 more elements
-40. (canceled)
Dependencies are inferred from the claim text.